Sunovion Pharma ciclesonide HFA gets FDA acceptance
The proposed dosing for ciclesonide HFA nasal aerosol is 74mcg once-daily (37mcg per spray; one-spray per nostril) Ciclesonide HFA is indicated for the treatment of symptoms of seasonal
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
A research conducted by LifeCycle Pharma demonstrated that certain types of intravenous chemotherapy can be modified, utilizing LifeCycle Pharma technologies, to pill-based therapy. Herlev Hospital Oncology Department chief